KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten U Niemann, Sandra Robrecht, Emelie C Rotbain, Laura Eurelings, Adam Giza, Julia von Tresckow, Can Zhang, Michael Gregor, Patrick Thornton, Philipp B Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Caspar da Cunha-Bang, Christof Schneider, Yair Herishanu, Derville O'Shea, Michael Baumann, Anouk Widmer, Thomas Nösslinger, Christian B Poulsen, Henrik Frederiksen, Kourosh Lotfi, Juha Ranti, Lisbeth Enggaard, Gerjo Velders, Marie-Christiane Vekemans, Koen de Heer, Tjeerd F Snijders, Claire Siemes, Clemens-Martin Wendtner, Wolfgang Knauf, Alexander Kroeber, Mark-Oliver Zahn, Thomas Illmer, Björn Schöttker, Florian Simon, Anna Fink, Kirsten Fischer, Ronald D'Brot, Emily Holmes, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Mark-David Levin, Michael Hallek, Arnon P Kater, Barbara Eichhorst

Blood 147(25) 3025-3038

PMID41911073
PMCID-
DOI10.1182/blood.2025032160
发表日期2026-03-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

Fixed-duration venetoclax combinations have become a standard first-line treatment in chronic lymphocytic leukemia (CLL). The phase 3 CLL13/GAIA trial assesses 3 time-limited combinations: venetoclax-rituximab (RV), venetoclax-obinutuzumab (GV), and venetoclax-obinutuzumab-ibrutinib (GIV), in comparison with chemoimmunotherapy (CIT). Fit patients with CLL without TP53 aberrations were randomized between 6 cycles of CIT (fludarabine-cyclophosphamide-rituximab [FCR] or bendamustine-rituximab [BR]) or 12 cycles of RV, GV, or GIV (GIV: ibrutinib continuation until cycle 36 if measurable residual disease at months 12/15). In total, 926 patients were randomized (GIV: 231, GV: 229, RV: 237, and CIT: 229 [FCR: 150, BR: 79]). With a median observation time of 63.8 months, 5-year progression-free survival (PFS) rates were 81.3% (GIV), 69.8% (GV), 57.4% (RV), and 50.7% (CIT). PFS was superior for GV and GIV compared with CIT and RV (P< .001 in each case). In addition, GIV showed longer PFS than GV (P = .0046). Venetoclax-based re-treatment after venetoclax-based first-line regimens was efficacious, with 2-year treatment-free survival >80% from second-line treatment. No differences in overall survival were observed between treatment arms (5-year rates: GIV, 94.3%; GV, 93.6%; RV, 94.7%; and CIT, 90.7%). The incidence rates of severe infections were highest with CIT, whereas cardiac events were most frequent with GIV. Compared with patients treated with CIT, those treated with GV or RV reported rapid and significantly greater quality-of-life (QoL) improvements. In the GIV arm, clinically relevant QoL improvements occurred later (month 15, after the end of treatment in most patients) than with GV/RV, likely due to a higher treatment-related symptom burden. This trial was registered at www.clinicaltrials.gov as NCT02950051.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。